Semaglutide Sodium vs Base: What FDA Says and What to Ask

Semaglutide sodium vs base comes down to identity, not math. The FDA-approved semaglutide products use semaglutide itself, often called the base form. FDA says salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients. It says it lacks information on whether they behave like the approved ingredient and is not aware of any lawful basis for using them in compounding (FDA, 2026). You can ask your pharmacy which form you have.

Key takeaways

• FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the one used in the approved drugs (FDA, 2026).
• FDA says it does not know whether these salts share the approved ingredient's chemical and pharmacologic properties, and it is not aware of any lawful basis for using them in compounding.
• Compounded medications, whatever form of an ingredient they use, are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are sold.
• A 503A pharmacy's bulk ingredients must meet federal conditions, including a registered manufacturer and a valid certificate of analysis, and you can ask about both (FDA 503A guidance).
• FDA has documented dosing errors and fraudulent labels involving compounded semaglutide, so the ingredient name and strength on your label are worth checking (FDA, 2024).

Semaglutide sodium vs base: what is the difference?

Semaglutide base is the semaglutide molecule on its own. Semaglutide sodium and semaglutide acetate are salt forms: the same core molecule paired with a counterion, which is a charged partner such as sodium or acetate.

That pairing is not a cosmetic detail. It changes the chemical identity of the ingredient a pharmacy buys, weighs and mixes.

FDA addresses this directly for semaglutide. In a section titled "Salt forms should not be used to compound semaglutide," FDA states that salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients from those used in the approved drugs (FDA, 2026).

So the honest answer to "semaglutide sodium vs semaglutide" is not a percentage. In FDA's view, they are two different ingredients.

Which form of semaglutide is in Ozempic and Wegovy?

The FDA-approved products contain semaglutide, not a semaglutide salt. FDA's statement that the sodium and acetate salts are different active ingredients from those in the approved drugs makes that distinction explicit (FDA, 2026).

FDA's 2024 dosing-error alert listed three FDA-approved semaglutide products: Wegovy injection, Ozempic injection and Rybelsus tablets (FDA, 2024). The current Wegovy label now covers both an injection and tablets, and it names the active ingredient simply as semaglutide (Wegovy label, 2026).

The salts are what show up on some compounding labels and seller pages. They are not what went through FDA approval.

Why FDA says salt forms should not be used in compounding

FDA's reasoning has two parts. It has no information showing the salts share the approved ingredient's chemical and pharmacologic properties, and it is not aware of any lawful basis for their use in compounding (FDA, 2026).

The second part makes more sense once you know the rules. Under section 503A of the federal drug law, a pharmacy compounding from a bulk drug substance (the raw active ingredient) has three routes to use it:

1. The substance meets an applicable monograph, an official quality standard published in the United States Pharmacopeia (USP) or National Formulary (NF), if one exists.
2. If no monograph exists, the substance is a component of an FDA-approved drug.
3. If neither applies, the substance appears on a list FDA develops through regulation.

FDA sets out these routes in its 503A guidance and interim policy (FDA 503A guidance; FDA interim policy).

Read against those routes, FDA's concern is easier to follow, though FDA's page does not walk through each route. The salts are not the ingredient in the approved drugs, and FDA says it has no data showing they act like it. FDA's chosen words are careful: it is "not aware of any lawful basis." It does not use words like "banned," and neither should a patient-facing page.

Timing adds context, because FDA says a compounded drug might be appropriate when a patient's need can't be met by an FDA-approved drug or the approved drug isn't commercially available (FDA, 2026). FDA determined on February 21, 2025, that the semaglutide injection shortage was resolved. Shortage-related enforcement discretion ended in April 2025 for 503A pharmacies, and FDA said it would not act on shortage-dependent violations by 503B outsourcing facilities until May 22, 2025 (FDA, 2025).

Are salt-form products the same medicine?

No. FDA calls them different active ingredients and says it lacks information on whether they share the approved ingredient's chemical and pharmacologic properties (FDA, 2026).

We found no verified clinical trial comparing salt-form and base-form semaglutide in people.

Conversion tables don't fix this. Salt-to-base math assumes that once you adjust for molecular weight, the salt behaves like the approved ingredient in the body. That is the exact assumption FDA says it has no information to support.

Here is the plain version. If a product needs salt-to-base math to "match" the approved drug, it is not the approved ingredient. Arithmetic cannot close a gap that FDA says it has no data on.

Why the ingredient on the label matters for safety

Knowing exactly what is in a vial, and how it is labeled, matters because FDA has documented real harm from confusion around compounded semaglutide. In July 2024, FDA reported adverse events possibly related to dosing errors with compounded injectable semaglutide, and some of those cases needed hospitalization (FDA, 2024).

The errors came from patients measuring incorrect doses and from health care providers miscalculating doses. Confusion between milliliters, milligrams and "units" may have contributed. In some reports, patients took five to 20 times the intended dose, mostly after drawing too much from multiple-dose vials. FDA also noted that semaglutide's half-life is about one week, so overdose symptoms may need a long period of observation. FDA encourages patients to talk with their provider or compounder about measuring the intended dose.

FDA's 2026 concerns page adds more (FDA, 2026):

• FDA is aware of fraudulent compounded semaglutide with false label information, including pharmacies that don't exist or didn't compound the product.
• Injectable GLP-1s need refrigeration. FDA has received complaints of products arriving warm and recommends not using an injectable GLP-1 that arrives warm.
• FDA set up an import alert to help keep GLP-1 active ingredients with potential quality concerns out of the U.S. supply chain.
• As of May 31, 2026, FDA had received 990 adverse event reports tied to compounded semaglutide. FDA can't always determine whether the drug caused an event, and underreporting is likely because pharmacies that are not outsourcing facilities don't have to report.

How to check which form your semaglutide uses

Start with the label, then ask the pharmacy directly. The paperwork that shows which ingredient was used already has to exist under the 503A rules.

For each bulk drug substance, a 503A pharmacy must use an ingredient made by an establishment registered with FDA under section 510. The ingredient must also come with a valid certificate of analysis (COA), the supplier's test document identifying the substance and its quality (FDA 503A guidance; FDA interim policy). Other ingredients must meet applicable USP/NF monographs and the USP compounding chapters. Our explainer on how certificates of analysis work in 503A compounding walks through what a COA shows.

Questions to ask any pharmacy or platform:

1. Which pharmacy compounds my medication, and is it a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility? FDA recommends filling prescriptions at a state-licensed pharmacy (FDA, 2026).
2. What exact active ingredient name appears on my label and on the bulk ingredient's COA: semaglutide, semaglutide sodium or semaglutide acetate?
3. Is the bulk ingredient's manufacturer registered under section 510?
4. Did a valid COA come with the bulk ingredient used for my batch?
5. Does my label state the strength clearly, and who do I contact with questions about it? FDA says to contact the compounder or telehealth platform with label questions.

FDA also lists telehealth red flags. These include claims that a compounded drug is the same as an FDA-approved drug, prices that look too good to be true, no screening and prescription by a licensed doctor, and spelling errors or wrong pharmacy addresses on the label. Pharmacies differ in what documents they share with patients, so ask plainly. Our compounded source verification checklist puts these checks in one place.

If your label lists a salt form, raise it with your prescribing clinician and the pharmacy before your next use. Don't change how you use the medication on your own. You can report suspected quality problems or side effects to FDA through its MedWatch program.

Safety screening that applies whatever the form

The safety screening on the semaglutide label applies to anyone considering any semaglutide product, whatever form it claims to contain. The Wegovy label has a boxed warning: semaglutide caused thyroid C-cell tumors in rodents, and whether it causes them in humans, including medullary thyroid carcinoma (MTC), is unknown (Wegovy label, 2026).

Wegovy is contraindicated in people with a personal or family history of MTC or with multiple endocrine neoplasia type 2 (MEN 2), an inherited condition that raises the risk of certain endocrine tumors. FDA has stated the same contraindication for Ozempic (FDA warning letter, 2025). Acute pancreatitis, meaning inflammation of the pancreas, has been seen with GLP-1 medications including Wegovy, and the label says to discontinue if pancreatitis is suspected. Acute gallbladder disease has also occurred in clinical trials.

People with a personal or family history of MTC or MEN 2, or a history of pancreatitis, should not use these medications, and a licensed clinician screens for this during review. Our GLP-1 eligibility checklist covers what screening usually looks at.

How access works through New Blue

New Blue is a technology and administrative services platform. Medical services are provided by independent licensed clinicians; medications are dispensed only if prescribed.

1. You complete an asynchronous intake, a structured questionnaire, which a licensed clinician reviews. Some treatments or states may require a live visit.
2. The clinician decides whether treatment is appropriate. Not everyone qualifies. Eligibility depends on your intake and clinical review, and that's how it should work.
3. If prescribed, a licensed partner pharmacy ships the medication directly to you.

Compounded semaglutide is not FDA-approved. It has the same active ingredient as Ozempic and Wegovy, which are FDA-approved brand products, and it is not equivalent to or a generic of either. Compounded medications are prepared by state-licensed 503A compounding pharmacies or FDA-registered 503B outsourcing facilities. Our compounding disclosure explains this further, and you can ask any of the questions above.

Availability varies by state. The Semaglutide GLP-1 pathway ships to every state New Blue Health serves except North Dakota. Check state availability before you start. For current pricing, see the Semaglutide GLP-1 pathway page. Consultation timing varies by clinician availability. If treatment isn't appropriate, refunds follow our refund policy. Adults 21+ only, and not for emergencies. New Blue is LegitScript certified.

Frequently Asked Questions

Is semaglutide sodium FDA-approved?

No. FDA says semaglutide sodium is a different active ingredient from the one used in the approved drugs, and it is not aware of any lawful basis for using it in compounding. No compounded semaglutide, base or salt, is FDA-approved, because FDA does not review compounded drugs before they are sold.

Is semaglutide sodium stronger or weaker than semaglutide base?

That question has no reliable numeric answer, because FDA says it lacks information on whether the salt behaves like the approved ingredient at all. Questions about your own dose belong with your clinician's guidance and the pharmacy instructions.

Is semaglutide sodium more stable than the base form?

No verified human or regulatory source we reviewed supports stability as a patient benefit of the salt forms. FDA's concern is ingredient identity and lawful use, not shelf life.

What about semaglutide acetate?

FDA groups semaglutide acetate with semaglutide sodium. Both are salt forms that FDA calls different active ingredients from the one in the approved drugs. The same lack of data and the same "no known lawful basis" position apply to both.

Does FDA's salt-form statement apply to tirzepatide?

FDA's salt-form statement is specifically about semaglutide. It should not be read as a statement about tirzepatide, but asking for the exact ingredient name, the manufacturer and the COA is reasonable for any compounded GLP-1. Tirzepatide questions are best taken to the prescribing clinician and the dispensing pharmacy.

Can I ask to see the certificate of analysis for my semaglutide?

You can ask. Under 503A rules, each bulk drug substance must be made by an establishment registered under section 510 and must come with a valid certificate of analysis. Pharmacies differ in what they share with patients, but asking which ingredient name appears on the COA is a reasonable question.

Sources

1. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration (CDER), 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
2. Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act (guidance). U.S. Food and Drug Administration. https://www.fda.gov/media/94393/download
3. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. U.S. Food and Drug Administration. https://www.fda.gov/media/174456/download
4. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration, 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
5. WEGOVY (semaglutide) injection and tablets: Highlights of Prescribing Information. U.S. Food and Drug Administration (Drugs@FDA label), 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
6. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. U.S. Food and Drug Administration, 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
7. Warning Letter: Novo Nordisk Inc. MARCS-CMS 716495. U.S. Food and Drug Administration, 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025

Medical disclaimer: This article is for educational purposes only and is not medical advice. Treatment decisions, including whether any medication is appropriate for you, are made by a licensed clinician based on your intake and clinical review. New Blue Health is a technology and administrative services platform, not a medical provider; medical services are provided by independent licensed clinicians, and medications are dispensed only if prescribed.